Passage Bio
Passage Bio is a fully integrated gene therapy company.
Launch date
Employees
Market cap
AUD77.0m
Enterprise valuation
(AUD24m) (Public information from Sep 2024)
Share price
$0.7 PASG
Philadelphia Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | <1m | <1m |
| % growth | - | - | - | - | - | - | (58 %) |
| EBITDA | (111m) | (170m) | (132m) | (93.9m) | (66.6m) | (68.1m) | (69.7m) |
| % EBITDA margin | - | - | - | - | - | (7173 %) | (17433 %) |
| Profit | (112m) | (185m) | (136m) | (102m) | (67.6m) | (80.6m) | (84.2m) |
| % profit margin | - | - | - | - | - | (8484 %) | (21063 %) |
| EV / revenue | - | - | - | - | - | 45.5x | 108.2x |
| EV / EBITDA | -9.3x | -1.3x | 0.9x | 0.6x | 0.3x | -0.6x | -0.6x |
| R&D budget | 81.8m | 118m | 86.1m | 61.4m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$116m | Series A | ||
$110m | Series B | ||
* | N/A | $216m | IPO |
* | N/A | $154m | Post IPO Equity |
| Total Funding | AUD349m | ||
Related Content
Recent News about Passage Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.